Trial Profile
The Effect of an SGLT2 inhibitor on Glucose Flux, Lipolysis and Ketogenesis following insulin withdrawal in people with absolute or relative endogenous insulin deficiency
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 15 Jul 2020
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Diabetes mellitus; Type 1 diabetes mellitus
- Focus Adverse reactions
- 08 Jul 2020 Results published in the Diabetes Care
- 24 Apr 2017 New trial record